For the Inventor, By the Inventor

Enter assignee name

Palo Alto, CA, United States of America

Syntex (u.s.a.) Inc.

USPTO Granted Patents = 932

% Expired Patents = 6.5

Trademarks = 13

Forward Citations = 19,869

Loading Chart...

Loading Chart...

666 inventors (with patents filed for the assignee):

Edwin F Ullman (65 out of 199 patents)

Robin D Clark (49 out of 74 patents)

Joseph M Muchowski (49 out of 53 patents)

4. Peter H Nelson (42 out of 53 patents)

5. Keith Adrian Walker (38 out of 42 patents)

6. Colin C Beard (35 out of 36 patents)

7. John H Fried (30 out of 46 patents)

8. Brian H Vickery (28 out of 33 patents)

9. Jurg R Pfister (26 out of 43 patents)

10. Eric Brian Sjogren (26 out of 64 patents)

11. Gordon H Jones (26 out of 28 patents)

12. Karl G Untch (26 out of 26 patents)

13. Arthur F Kluge (23 out of 96 patents)

14. Michael C Venuti (23 out of 25 patents)

15. Denis John Kertesz (22 out of 29 patents)

Core Competencies:

Anti-Inflammatory Agents

Receptor Antagonists

Kinase Inhibitors

Nerve Growth Factor

Mucin Production

Sodium Channel Modulation

Glycosyl Sulfotransferases

Quinazolone Derivatives

Pyrazole Derivatives

Muscarinic Receptor Antagonists

Retinoid Compounds

Heterocyclic Compounds

932 patents: Sort by Forward Citations

1. 7186841 - Antiinflammation agents (2007-03-06),

2. 7141365 - Methods for diagnosing a mucin production associated disease condition (2006-11-28),

3. 7122325 - Method of modulating tetrotodoxin-resistant sodium channel (2006-10-17),

4. 7094778 - Heterocyclylalkylamines as muscarinic receptor antagonists (2006-08-22),

5. 7094591 - Human aggrecanase and nucleic acid compositions encoding the same (2006-08-22),

6. 7091200 - Quinazolone derivatives as alpha 1A/B adrenergic receptor antagonists (2006-08-15),

7. 7074763 - Stable formulations of nerve growth factor (2006-07-11),

8. 7071177 - P-(sulfonyl) aryl and heteroarylamines as anti-inflammatory agents (2006-07-04),

9. 7070971 - Glycosyl sulfotransferases GST-4α, GST-4β, and GST-6 (2006-07-04),

10. 7056903 - Carboxylic acid derivatives as IP antagonists (2006-06-06),

11. 7053103 - Ring fused pyrazole derivatives as CRF antagonists (2006-05-30),

12. 7049325 - Quinoline derivatives as anti-inflammatory agents (2006-05-23),

13. 7049317 - CCR-3 receptor antagonists (2006-05-23),

14. 7019007 - CCR-3 receptor antagonists (I) (2006-03-28),

15. 6984637 - Cyclic amine derivatives-CCR-3 receptor antagonists (2006-01-10),

Syntex (U.S.A.) Inc., based in Palo Alto, CA, specializes in the development of innovative anti-inflammatory agents. The company focuses on advanced therapeutic solutions that target various mechanisms involved in inflammation, including receptor antagonists and kinase inhibitors. Their research encompasses critical areas such as nerve growth factor modulation, mucin production, and sodium channel modulation, contributing to the advancement of treatments for inflammatory conditions. Syntex is committed to enhancing patient outcomes through cutting-edge scientific exploration.

Profile summary based on public USPTO records.

Company Badge

USPTO Data Jan 1 1976 - Oct 6 2026

932 Patents

#6 in Palo Alto, CA

#134 in California

#558 in US

#1,094 in the World

Palo Alto, CA, United States of America

Syntex (u.s.a.) Inc.

Forward Citations = 19,869

666 inventors:

Edwin F Ullman (65 out of 199 patents)

Robin D Clark (49 out of 74 patents)

Joseph M Muchowski (49 out of 53 patents)

4. Peter H Nelson (42 out of 53 patents)

5. Keith Adrian Walker (38 out of 42 patents)

Please report any incorrect information to [email protected]

Loading…